Journal article
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
- Abstract:
-
Recurrent mutations in isocitrate dehydrogenase 2 (IDH2) occur in ∼12% of patients with acute myeloid leukemia (AML). Mutated IDH2 proteins neomorphically synthesize 2-hydroxyglutarate resulting in DNA and histone hypermethylation, which leads to blocked cellular differentiation. Enasidenib (AG-221/CC-90007) is a first-in-class, oral, selective inhibitor of mutant-IDH2 enzymes. This first-in-human phase 1/2 study assessed the maximum tolerated dose (MTD), pharmacokinetic and pharmacodynamic p...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
- Version:
- Accepted Manuscript
Actions
Access Document
- Files:
-
-
(pdf, 158.7KB)
-
- Publisher copy:
- 10.1182/blood-2017-04-779405
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Bibliographic Details
- Publisher:
- American Society of Hematology Publisher's website
- Journal:
- Blood Journal website
- Volume:
- 130
- Issue:
- 6
- Pages:
- 722-731
- Publication date:
- 2017-06-06
- Acceptance date:
- 2017-05-19
- DOI:
- EISSN:
-
1528-0020
- ISSN:
-
0006-4971
- Pubs id:
-
pubs:699355
- URN:
-
uri:0d4137c0-dbff-4bfc-ad82-78cecc6ca2bb
- UUID:
-
uuid:0d4137c0-dbff-4bfc-ad82-78cecc6ca2bb
- Local pid:
- pubs:699355
Item Description
- Language:
- English
Terms of use
- Copyright holder:
- American Society of Hematology
- Copyright date:
- 2017
- Notes:
- © 2017 by The American Society of Hematology. This is the accepted manuscript version of the article. The final version is available online from American Society of Hematology at: https://doi.org/10.1182/blood-2017-04-779405
If you are the owner of this record, you can report an update to it here: Report update to this record